Talk:Brodalumab

From WikiProjectMed
Jump to navigation Jump to search

Boxed warning etc may limit/delay use

Prescribing Barriers in Psoriasis says "Concerns about increased risks of suicidal ideation and behavior in phase III studies were so great that the FDA approved brodalumab with a boxed warning and instituted a Risk Evaluation and Mitigation Strategy (REMS) program that raises barriers to prescribing the drug." The REMS is not yet defined so presumably Siliq is not yet available for use/sale/prescription. What should we say ? - Rod57 (talk) 12:58, 24 July 2017 (UTC)[reply]